Companies: 10,795·Total market cap: $144.5T
Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.

ALLONASDAQHealthcare● Active
$1.85
$-0.03(-1.60%)
Market Cap$451158381
P/E Ratio
52W High$4.46
52W Low$0.98

Allogene Therapeutics, Inc. (ALLO) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

allo · stock forecast · 30 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 30 Wall Street analysts in the past 3 months

SellBuy

Buy

30 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
19
Hold
10
Sell
1
Strong Sell
0
Total: 30 · Buy rate: 63.3%

12-Month Price Target

High

$9.00

Consensus

$6.43

+247.6% upside

Low

$3.85

Median: $6.425 · Last Close: $1.85

The Allogene Therapeutics, Inc. (ALLO) analyst consensus is Buy, based on ratings from 30 Wall Street analysts over the past 3 months. The average 12-month ALLO price target is $6.43, representing +247.6% upside from the current price of $1.85.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $6 (247.6%)

Consensus Target

$6.43

247.6% upside

High Target

$9

386.5%

Low Target

$3.85

108.1%

Current Price

$1.85

as of today

Based on analyst price targets, the ALLO stock price prediction for the next 12 months ranges from $3.85 to $9. The consensus ALLO price forecast of $6.43 implies 247.6% upside from the current price of $1.85.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$1.793.15%

1-day model range: $1.76–$1.82. Peak: $1.82 (-3.15%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027-21.2%
2028-30.4%
2029-34.9%
2030-37.2%
2031-38.4%
Confidence:Very Low
⚠️ 2027 projections carry Very Low confidence. Treat as directional guidance only.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)44.9
MACDBEARISH

Moving Averages · ALLO · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$1.96SELL
MA 10$2.08SELL
MA 20$2.08SELL
MA 50$2.26SELL
MA 100$2.16SELL
MA 200$1.73BUY
Current $ALLO · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$1.95SELL
EMA 10$2.01SELL
EMA 20$2.08SELL
EMA 50$2.16SELL
EMA 100$2.08SELL
EMA 200$1.89SELL
Current $ALLO · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-04-16
Maintains
BuyBuy
JP Morgan2026-04-16
Upgrade ↑
UnderweightNeutral
Jefferies2026-04-15
Maintains
BuyBuy
Argus Research2026-04-14
Maintains
Market PerformMarket Perform
HC Wainwright & Co.2026-04-14
Maintains
BuyBuy
Citizens2026-04-14
Maintains
Market OutperformMarket Outperform
Baird2026-04-14
Maintains
OutperformOutperform
Bernstein2026-04-14
Maintains
Market PerformMarket Perform
Canaccord Genuity2026-03-13
Maintains
BuyBuy
Piper Sandler2026-03-13
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Allogene Therapeutics, Inc. (ALLO) stock. Of the recent 118 rating actions, 12 were upgrades and 10 were downgrades. 30 analysts currently cover ALLO.

Analyst Recommendation Trends

Buy ratings651
Hold ratings03↑ +3
Sell ratings00

ALLO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 6 to 5 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↓ 100.0% YoY

Revenue Next Year

$10M

↑ 78682.1% YoY

EPS This Year

$-0.72

EPS Next Year

$-0.80

↑ 11.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ALLO EPS of $-0.72 for the current fiscal year, based on estimates from 9 analysts. The ALLO revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ALLO stock forecast is supported by two independent data sources: analyst consensus ratings from 30 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ALLO price target is $6.43 (+247.6% upside), with an analyst consensus of Buy.

The ALLO short-term stock prediction for tomorrow is $1.79 (-3.15%). The ALLO stock prediction for 2030 projects a range of $1–$1.

Allogene Therapeutics, Inc. trades on NASDAQ under the ticker ALLO. The ALLO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ALLO forecast · 8 questions

According to 30 Wall Street analysts, the average 12-month ALLO price target is $6.43, with a high forecast of $9.00 and a low of $3.85. The median price target is shown in the chart above when available. This implies +247.6% potential upside from the current price of $1.85.

ALLO price targetWhat is ALLO price targetALLO analyst price targetALLO 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.